All Stories

  1. COVID 19 Study, Drug Selection and Development
  2. Anticancer Drug Combinations: Different Strategies Used in the Clinic
  3. Cancer Bioinformatics, New Chapter of Personalized Medicine
  4. Pulmonary nodules, knowledge renovation and comprehensive studies
  5. Personalized Oncology: Scientific and Technical Approaches
  6. Advances in Cancer Therapeutics and Genomics for Improved Patient Outcomes
  7. Magnetic water and clinical cancer chemotherapy
  8. Human suicide, clinical treatment overview
  9. Sexually transmitted disease diagnosis and treatments, risk factors from beyond
  10. Human suicide, risk factors and new perspective
  11. Suicide study, new approaches
  12. Human suicide, molecular framework
  13. COVID-19 knowledge and therapeutics, past, present and future
  14. Artificial intelligence for advancing nursery service
  15. Treatment improvements by pediatric Theranostics
  16. COVID-19 conception advances, epidemics, pathology and therapeutics
  17. Withdrawn: Professor Bin Xu, A Legendary Pharmacologist in People’s Republic of China
  18. Sialic Acids and Cancer: Pathophysiological Association between Metastatic Progress and Treatment
  19. Anticancer Drug Development, Pharmaceutical Progress
  20. Human Suicide, Biomedical Knowledge Advances
  21. Type 2 Diabetes Treatments in Countries of Different Economic Status
  22. Human suicide, biomedical knowledge and therapeutic advances
  23. Human Suicide, an Overview of Management Strategies
  24. COVID-19 Research, Public Health and Biomedical Basis
  25. Human Suicide, Management Landscape
  26. Anticancer Drug Development: Evaluative Architecture
  27. COVID-19 Study: A New Principle Discovery
  28. COVID-19 Study, Diagnostic and Therapeutic Transition
  29. Antimetastatic Drug, Pharmacologic Challenge and Opportunity
  30. Nursery services advances, global campaign
  31. Different approaches to bone transplantation surgery
  32. Bone Metastasis Diagnosis, Blood Biomarker Detections
  33. Anti-metastatic drug development, overview and perspectives
  34. Educational Perspectives for Nursery
  35. Is Tau Molecule Regarded as a Risk Factor for Human Suicide?
  36. Drug Sensitivity Testing for Cancer Therapy, Technique Analysis and Trends
  37. Suicide Curative Treatment Study and Drug Development
  38. Pulmonary nodules, is there any pathogenesis evidence?
  39. HIV/AIDS Curability Study, Different Approaches and Drug Combination
  40. Pulmonary nodules, surgery or other medication
  41. Bone Metastasis and Circulation Biomarkers Profiling Towards Personalized Cancer Medicine
  42. Pulmonary Nodules, Surgery or Other Medication
  43. Anti-Metastatic Drug Developments, Utility of More Animal Models
  44. Several approaches for anticancer drug development progress
  45. Drug Sensitivity Testing for Cancer Therapy, Key Areas
  46. COVID-19 infection for metabolic abnormal human beings
  47. Fundamental knowledge for nurses 
  48. Nursery promotion, education and system updating
  49. Cancer Bone Metastasis, Diagnostic Insights and Drug Selection
  50. Covid-19 Study, Pathology and Therapeutics
  51. Acupuncture for Bone Disease Treatments, Modern Approaches
  52. Cancer Bone Metastasis, Experimental Study
  53. Neuropsychiatric Approaches for Human Suicide Prediction and Management
  54. Osteoporosis Targeting, Possible Breakthroughs
  55. Neuropsychiatric insights for human suicide
  56. Bone Cancer and Metastasis Trials, Drug Treatment
  57. Neurobiology for human suicide
  58. Bone Disease Treatment Study, Major Pathways
  59. Pathology Study for Human Suicide
  60. Nursery activity and quality, chemistry between doctors and nurses
  61. Nursery education, narrow-range or wide-range
  62. Anticancer drug development, challenge and dilemma
  63. Life Origin on Earth, Knowledge Development
  64. HIV/AIDS treatment, therapeutic strategy break throughs
  65. Nursery education for diabetes
  66. Suicide Risks and Prevention, Neuropathogenic Study
  67. Medical Treatments for Chronic or Aggressive Diseases, Palliative Therapy and Nursery
  68. General information for nursery
  69. Historical analysis of suicide
  70. Drug sensitivity testing, a unique drug selection strategy
  71. Natural drug cancer treatments, strategies from herbal medicine to chemical or biological drugs
  72. Medical treatments for incurable diseases, palliative therapy
  73. Life Origin on Earth, Biochemical Approaches
  74. Nursery training, from technique details in schools into medical knowledge education in nursery career
  75. Herbal medicine in new era
  76. Nursery service, quality promotion
  77. Anti-Metastatic Drug Developments, Biomedical Mechanisms and Therapeutic Categorization
  78. Patient’s care and nursery in different diseases
  79. Ebola Therapeutic Study and Future Directions
  80. New HIV/AIDS Therapeutics
  81. Nursery Service in Modern Days
  82. Nursery Education, Capability and Service Promotion
  83. Nursery Science and Conventions
  84. Cancer Bioinformatics in Cancer Therapy
  85. Individualized Cancer Therapy
  86. Human Suicide Risk and Treatment Study
  87. Type 2 Diabetes Treatment and Drug Development Study
  88. Hypotheses for Life Origin on Earth, Comparison and Validation
  89. Type 2 Diabetes Study, Introduction and Perspective
  90. Type 2 Diabetes Mellitus Study, A Process of Enigma unraveling
  91. Anthocyanins and its biological & therapeutic characters
  92. Diabetes Prevention and Treatments, a Specific Topic for Modern Medicines
  93. A Critical Appraisal of Different Food Safety and Quality Management Tools to Accomplish Food Safety
  94. Pathology and treatments of obesity
  95. Obesity, Risks and Managements
  96. Keep up the pace of drug development evolution and expenditure
  97. An Overview of Obesity
  98. General Topics in the Field of Personalized Cancer Therapy
  99. Human Suicide Risk Study and Treatment: A Mathematical Approach
  100. Anti-Metastatic Drug Developments: Work Out towards New Direction
  101. Diabetes Mellitus and Male Aging: Pharmacotherapeutics and Clinical Implications
  102. Drug Combination in Clinical Cancer Treatments
  103. General outlook for individualized cancer therapy
  104. Ebola origin and treatment
  105. Different Disciplines in the Field of Suicide Study
  106. Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics
  107. HAART in HIV/AIDS Treatments
  108. Anticancer Drug Development, System Updating and Global Participations
  109. Life Origin on Earth, What is the Right Answer?
  110. Life Origin on Earth, What is the Right Answer?
  111. Anticancer Drug Development, Getting out from Bottleneck
  112. Anticancer Drug Development, Getting out from Bottleneck
  113. Human suicide study, major disciplines and treatment outcomes
  114. Anticancer drug development
  115. HIV in Human Genomes and Therapeutics
  116. HIV Biotherapy and Natural Chemotherapeutic Agents
  117. Anticancer Drug Combinations, How Far We can Go Through?
  118. Antimetastatic therapy at aberrant sialylation in cancer cells, a potential hotspot
  119. Life Origin on Earth, Insights among Different Arguments
  120. Genetics in Suicide Treatments, Modern Diagnosis Establishments
  121. Diabetes Preventions and Treatments, a Specific Topic for Modern Medicines
  122. Anticancer Drug Development, Breakthroughs are Waiting
  123. Cancer metastasis treatment, a key drawbacks
  124. The suicide treatment, a new model
  125. HIV Vaccine for Prevention and Cure, A Mission Possible
  126. Zika Therapy
  127. HIV vaccine
  128. Discover Natural Chemical Drugs in Modern Medicines
  129. Mathematics in biomedical science
  130. The origin of HIV
  131. Human suicide study
  132. Mathematics or Physics-Majored Students on the Biomedical Fields, Insiders or Outsiders?
  133. Pharmacogenetics of Cancer Therapy
  134. Anticancer Drug Sensitivity Testing
  135. New Perspectives of HIV/AIDS Therapy Study
  136. Antidepressant treatment study
  137. Clinical neoplasm metastasis treatments according to patient's personal conditions.
  138. Assistant cancer treatments in the clinic
  139. Drug sensitivity testing in clinical cancer treatments
  140. Anticancer drug combination in the clinic
  141. Anticancer drug pharmacogenomics in cancer chemotherapy
  142. Cost-effectiveness for personalized cancer therapy
  143. Conclusion
  144. Introduction
  145. Discussion
  146. Cancer biomarker/bioinformatics detection in clinical cancer treatments
  147. Anti-diabetic treatments
  148. Anticancer Drug Combinational Study
  149. The Origins of HIV
  150. Plasma Fibrinogen Concentrations in Patients with Solid Tumors and Therapeutic Improvements by Combining Anticoagulants or Fibrinolytical Agents
  151. Anticancer Drug Combinations, A Big Momentum is Needed
  152. Anticancer Drug Development, a Matter of Money or a Matter of Idea?
  153. Future Perspectives for Controlling Ebola Epidemics
  154. Ebola Origin and Therapies
  155. Cancer Bioinformatics, its Impacts on Cancer Therapy
  156. Copyright
  157. List of figures and tables
  158. Anti-diabetic treatments, patho-therapeutic relation
  159. Origin of Ebola, hypothesis
  160. Personalized Cancer Therapy: A Perspective
  161. Rethink Of Diabetes Treatment and Drug Development
  162. Pharmacogenomics in human suicide prediction and treatments
  163. Cancer metastasis treatment study and drug developments
  164. Challenge for HIV/AIDS therapy
  165. Cost-effectiveness Considerations of Individualized Cancer Chemotherapy
  166. Drug Combinations in Cancer Treatments
  167. New Insights into Individualized Antimetastatic Therapy
  168. Anticancer drugs on serum sialic acid level in mice bearing LLC
  169. Drug Combinations in Cancer Treatments
  170. Genetics in Neural Toxicity of Drugs
  171. Avian flu, pathogenesis and therapeutic study
  172. First Genetic Information Replication in Life Origin on Earth
  173. Origins of Life, A New Cooperative Model
  174. Cancer Metastases and Clinical Therapies
  175. Origins of Life, RNA world or alternative RNA world
  176. Development of Antimetastatic Drugs by Targeting Tumor Sialic Acids
  177. Individualized Cancer Chemotherapy by Detecting Cancer Biomarkers
  178. Antimetastatic Therapies according to Metastatic Cascade
  179. Genetics in antidepressant-induced suicide
  180. Pathology of Drug-induced mania & suicide
  181. Influenza treatment
  182. High Active Anti-retroviral Therapy for HIV/AIDS, Progresses and Drawback
  183. Individualized cancer chemotherapy
  184. High Active Antiretroviral Therapy for HIV/AIDS-Early Intervention or Later Intervention?
  185. The Hypotheses for the Pathogeny of Drug-Induced Mania and Suicide
  186. The Relationship between Tumor Sialic Acids and Neoplasm Metastasis and as a Drug Target
  187. Genomic study of antidepressant-induced suicide
  188. Aberrant sialylation in tumor cells
  189. Anti-mobility of Bisdioxopiperanes against human mammary tumors
  190. Antimetastatic activity and mechanisms of action of Bisdioxopiperazine compounds
  191. Neural toxicity of drugs
  192. Anticancer activity and mechanisms of Bisdioxopiperazines
  193. Different Spontaneous Pulmonary Metastasis Inhibitions against Lewis Lung Carcinoma in Mice by Bisdioxopiperazine Compounds of Different Treatment Schedules
  194. 14C-probimane in the mice bearing LLC
  195. Unsatisfactory design of human AIDS genome research
  196. Antidepressant in Cancer Treatment
  197. AIDS and human genome studies, from a hypothesis to systematic approaches
  198. Antidepressants in Human suicide
  199. Mathematical model in therapeutic risk prediction
  200. Fibrinogen in neoplasm metastasis
  201. Sequencing the whole genome of infected human cells obtained from diseased patients – a proposed strategy for understanding and overcoming AIDS or other deadest virus-infected diseases
  202. Relationship Between Blood Fibrinogen Concentration and Pathological Features of Cancer Patients: A 139-case Clinical Study
  203. Medicinal Chemistry of Probimane and MST-16: Comparison of Anticancer Effects Between Bisdioxopiperazines
  204. Individualized cancer chemotheray
  205. Anti-proliferative and chromosome segregation by probimane and MST-16
  206. Effect of Anti-Cancer Drugs on the Binding of 125I-Fibrinogen to Two Leukaemia Cell Lines In Vitro
  207. Antitumor effects of two bisdioxopiperazines against two experimental lung cancer models in vivo
  208. Inhibition of probimane on lipid peroxidation of rabbit and human erythrocytes
  209. Aberration of sialylation in neoplasm metastasis and possible therapeutics
  210. Effects of Cancer Chemotherapy on the Blood Fibrinogen Concentrations of Cancer Patients
  211. Effect of magnetized water on the mice given high doses of antineoplastic drugs
  212. Inhibition of probimane on lipoperoxidation of human red cells in vitro
  213. Enzyme dynamic study on calmodulin Ca++-Mg++-ATPase system of red blood cells inhibited by α-anordrin and probimane
  214. Journal of Clinical and Medical Reviews